AmbioPharm: difference between revisions

Diff·revision 7 → 8·00:25, 1 Nov 2025

Difference between revision 7 and revision 8 of AmbioPharm. 8 lines changed; the page grew by 1,561 bytes.

Revision 7 — 20:12, 24 Oct 2025 VerifyVesna (talk) correct the other-designations row — those are trading variants, not subsidiaries 4,517 bytes +184	Revision 8 — 00:25, 1 Nov 2025 GMP_Gita (talk) rm a duplicated category 6,078 bytes +1,561
27	The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.	27	The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report.
28		28
+		29	== Operations and documentation practice ==
+		30	Purchaser reports describe vialled lyophilised material arriving with a batch-specific [[Certificate of analysis\|certificate]] naming a [[Batch number\|lot]], and across the submitted set the lot string on the certificate has corresponded to the vial label.{{r\|reports}} That correspondence is a minimum requirement rather than an achievement.
+		31
+		32	Two determinations distinguish the submitted set from most entities covered here. Water content by [[Karl Fischer titration\|Karl Fischer titration]] appears on the certificates described, and the [[Counter-ion\|counter-ion]] is reported as a figure with its unit rather than named or omitted.{{r\|reports,usp1503}} Together with [[Peptide content\|peptide content]] on a separate line from chromatographic purity, those are what let a purity percentage be read as a statement about mass. Their routine presence is the most useful documentary observation available about this organisation. Reports also describe the release as signed and dated by a named individual rather than initialled.{{r\|reports}}
+		33
29	== References ==	34	== References ==
30	{{reflist}}	35	{{reflist}}
31	<ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref>	36	<ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref>
32	<ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref>	37	<ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref>
+		38	<ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref>
33	<ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref>	39	<ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref>
+		40	<ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref>
34	<ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref>	41	<ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref>
35		42
⋮		⋮
38	[[Category:Suppliers in China]]	45	[[Category:Suppliers in China]]
39	[[Category:Certificates of analysis]]	46	[[Category:Certificates of analysis]]
+		47	[[Category:Testing methodology]]
40		48